文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19合并严重低氧血症ICU患者低氧合目标与高氧合目标的长期死亡率及健康相关生活质量比较

Long-term mortality and health-related quality of life with lower versus higher oxygenation targets in intensive care unit patients with COVID-19 and severe hypoxaemia.
PubMed 文献 · Intensive Care Med · 2024-09-05
一句话结论在COVID-19合并严重低氧血症的ICU患者中,一年死亡率结果与低氧合目标(8 kPa)获益最为相符,且未出现更多生活质量差的存活者。

该研究为Handling Oxygenation Targets in COVID-19试验的预设分析,纳入726例COVID-19合并低氧血症的ICU患者,随机分为动脉血氧分压目标8 kPa(60 mmHg)组与12 kPa(90 mmHg)组,干预持续至ICU停留90天(含再入院)。一年时低氧合组死亡117/348(33.6%),高氧合组死亡134/343(39.1%),校正风险比0.85(98.6%CI 0.66-1.09;p=0.11)。EQ-VAS中位数低氧合组50(0-80)vs高氧合组40(0-75),校正均值差4.8(98.6%CI -2.2至11.9;p=0.09);EQ-5D-5L指数值低氧合组0.61(0-0.81)vs高氧合组0.43(0-0.79)(p=0.20)。结论认为一年死亡率结果与低氧合目标获益最为相符,且未出现更多生活质量差的存活者。

要点

  • 在COVID-19合并严重低氧血症的ICU患者中,低氧合目标(8 kPa,60 mmHg)组一年死亡117/348(33.6%),高氧合目标(12 kPa,90 mmHg)组死亡134/343(39.1%),校正RR 0.85(98.6%CI 0.66-1.09;p=0.11)。
  • 低氧合组EQ-VAS中位数50(0-80)vs高氧合组40(0-75),校正均值差4.8(98.6%CI -2.2至11.9;p=0.09)。
  • 低氧合组EQ-5D-5L指数值0.61(0-0.81)vs高氧合组0.43(0-0.79)(p=0.20)。
  • 一年生存状态获取率691/726(95.2%),HRQoL数据获取率642/726(88.4%)。

适用人群与场景

  • 纳入COVID-19合并低氧血症的成人ICU患者,随机接受动脉血氧分压目标8 kPa(60 mmHg)或12 kPa(90 mmHg),干预持续至ICU停留90天(含再入院)。
  • 分析基于意向治疗人群,非存活者HRQoL赋值为最差分值(零),EQ-VAS缺失值采用多重插补。

处置流程与药物剂量

  • 动脉血氧分压目标:低氧合组8 kPa(60 mmHg),高氧合组12 kPa(90 mmHg),干预持续至ICU停留90天(含再入院)。

研究设计与关键结果

  • 研究类型为Handling Oxygenation Targets in COVID-19试验的预设分析,随机726例ICU患者,比较动脉血氧分压目标8 kPa(60 mmHg)与12 kPa(90 mmHg)。
  • 一年时低氧合组死亡117/348(33.6%),高氧合组死亡134/343(39.1%),校正风险比0.85(98.6%CI 0.66-1.09;p=0.11)。
  • EQ-VAS中位数低氧合组50(四分位距0-80)vs高氧合组40(0-75),校正均值差4.8(98.6%CI -2.2至11.9;p=0.09)。
  • EQ-5D-5L指数值低氧合组0.61(0-0.81)vs高氧合组0.43(0-0.79)(p=0.20)。
  • 一年生存状态获取691/726(95.2%),HRQoL数据获取642/726(88.4%)。

证据类型、等级与局限

  • 证据类型:随机对照试验的预设分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 在COVID-19合并严重低氧血症的成人ICU患者中,一年死亡率结果与低氧合目标(8 kPa,60 mmHg)获益最为相符,且未出现更多生活质量差的存活者。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

PURPOSE: The aim of this study was to evaluate one-year outcomes of lower versus higher oxygenation targets in intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19) and severe hypoxaemia.

METHODS: We conducted pre-planned analyses of one-year mortality and health-related quality of life (HRQoL) in the Handling Oxygenation Targets in COVID-19 trial. The trial randomised 726 ICU patients with COVID-19 and hypoxaemia to partial pressure of arterial oxygen targets of 8 kPa (60 mmHg) versus 12 kPa (90 mmHg) during ICU stay up to 90 days, including readmissions. HRQoL was assessed using EuroQol visual analogue scale (EQ-VAS) and 5-level 5-dimension questionnaire (EQ-5D-5L). Outcomes were analysed in the intention-to-treat population. Non-survivors were assigned the worst possible score (zero), and multiple imputation was applied for missing EQ-VAS values.

RESULTS: We obtained one-year vital status for 691/726 (95.2%) of patients and HRQoL data for 642/726 (88.4%). At one year, 117/348 (33.6%) of patients in the lower-oxygenation group had died compared to 134/343 (39.1%) in the higher-oxygenation group (adjusted risk ratio: 0.85; 98.6% confidence interval (CI) 0.66-1.09; p = 0.11). Median EQ-VAS was 50 (interquartile range, 0-80) versus 40 (0-75) (adjusted mean difference: 4.8; 98.6% CI - 2.2 to 11.9; p = 0.09) and EQ-5D-5L index values were 0.61 (0-0.81) in the lower-oxygenation group versus 0.43 (0-0.79) (p = 0.20) in the higher-oxygenation group, respectively.

CONCLUSION: Among adult ICU patients with COVID-19 and severe hypoxaemia, one-year mortality results were most compatible with benefit of the lower oxygenation target, which did not appear to result in more survivors with poor quality of life.

来源:Intensive Care Med,查看原文。版权归原作者所有。

参考来源

  1. Crescioli E, Nielsen FM, Bunzel AM, et al. Long-term mortality and health-related quality of life with lower versus higher oxygenation targets in intensive care unit patients with COVID-19 and severe hypoxaemia. Intensive Care Med. 2024. PMID: 39235624. doi:10.1007/s00134-024-07613-2

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。